Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study
- Conditions
- Hypertrophic Cardiomyopathy
- Registration Number
- NCT02424994
- Lead Sponsor
- University College, London
- Brief Summary
The aim of this project is to study the association of a number of demographic and cardiovascular risk factors with death, health care utilisation and systemic embolisation by examining the clinical evolution of hypertrophic cardiomyopathy in a large, community based cohort identified from linked electronic health records.
- Detailed Description
Most data on hypertrophic cardiomyopathy related morbidity and mortality are derived primarily from longitudinal, observational studies based at tertiary cardiac centres. It is unclear what the main causes of morbidity and death are in the general hypertropic cardiomyopathy population (outside tertiary referral centres) and it is likely that many patients have a benign clinical course and die from non-cardiac causes.
Linkage of the Clinical Practice Research Datalink (CPRD) to the Myocardial Ischaemia National Audit Project (MINAP), Hospital Episode Statistics (HES) and Office of National Statistics (ONS), offers the opportunities to study the natural history of hypertrophic cardiomyopathy, from the time of diagnosis to the end of life, health care utilisation and to investigate the association between clinical characteristics and common clinical fatal and non-fatal outcomes.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12464
- One year or more of follow-up in the practice prior to study entry
- 18 years or older
• Unknown sex and age
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate ratios for the associations between hypertrophic cardiomyopathy and coronary heart disease not otherwise specified Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and angina Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and myocardial infarction Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and cardiac arrest Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and unstable angina Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and abdominal aortic aneurysm Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and ventricular arrhythmia Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and atrial fibrillation Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and transient ischemic attack Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and stroke Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and peripheral arterial disease Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and systemic thromboembolism Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and heart failure Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years)
- Secondary Outcome Measures
Name Time Method Rate ratios for the associations between hypertrophic cardiomyopathy and cancer Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and chronic obstructive pulmonary disease Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years) Rate ratios for the associations between hypertrophic cardiomyopathy and liver-related Followed for the duration of general practice registration between date of eligibility and date of administrative censoring, outcome occurrence or death (expected median of 4 years)
Trial Locations
- Locations (1)
University College London Farr Institute of Health Informatics Research
🇬🇧London, United Kingdom